Journal
NEUROBIOLOGY OF DISEASE
Volume 27, Issue 1, Pages 11-23Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2007.03.013
Keywords
L-DOPA; dyskinesia; Parkinson's disease; fosB; striatum; aphakia mouse
Categories
Funding
- NIGMS NIH HHS [T32 GM07839, T32 GM007839] Funding Source: Medline
- NIMH NIH HHS [R01 MH48866, R01 MH048866] Funding Source: Medline
- NINDS NIH HHS [R01 NS032080-09A1, R01 NS032080-07, R01 NS032080-11, R01 NS032080-08S1, R01 NS032080, R01 NS032080-10, R01 NS32080, R01 NS043286, R01 NS032080-12, R01 NS032080-08, R01 NS43286, R01 NS032080-07S1, R01 NS032080-13] Funding Source: Medline
Ask authors/readers for more resources
L-DOPA-induced dyskinesia (LID) is one of the main limitations of long term L-DOPA use in Parkinson's disease (PD) patients. We show that chronic L-DOPA treatment induces novel dyskinetic behaviors in aphakia mouse with selective nigrostriatal deficit mimicking PD. The stereotypical abnormal involuntary movements were induced by dopamine receptor agonists and attenuated by antidyskinetic agents. The development of LID was accompanied by preprodynorphin and preproenkephalin expression changes in the denervated dorsal striatum. Increased FosB-expression was also noted in the dorsal striatum. In addition, FosB expression was noted in the pedunculopontine nucleus and the zona incerta, structures previously not examined in the setting of LID. The aphakia mouse is a novel genetic model with behavioral and biochemical characteristics consistent with those of PD dyskinesia and provides a more consistent, convenient, and physiologic model than toxic lesion models to study the mechanism of LID and to test therapeutic approaches for LID. (c) 2007 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available